Cognition Therapeutics, Inc. (CGTX) Free cash flow
- Free cash flow · 12 months (USD): Value (m); Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | (m) | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | (m) | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-17.68M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 1.05× | Operating cash flow / net income. Period ending 2026-06-30. $-17.68M ÷ $-16.77M ≈ 1.05× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -17.68M USD | Net Cash Provided by (Used in) Operating Activities |
| Capital spending | (m) | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | (m) | Net Cash Provided by (Used in) Operating Activities · Payments to Acquire Property, Plant, and Equipment |
| Revenue | (m) | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -16.77M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $-17.68M | (m) | (m) | (m) | (m) | $-16.77M | (m) | (m) | (m) | 1.05× |
| 2026-03-31 | (m) | (m) | $-20.25M | (m) | (m) | (m) | (m) | $-19.58M | (m) | (m) | (m) | 1.03× |
| 2025-12-31 | (m) | (m) | $-24.59M | (m) | (m) | (m) | (m) | $-23.49M | (m) | (m) | (m) | 1.05× |
| 2025-09-30 | (m) | (m) | $-29.53M | (m) | (m) | (m) | (m) | $-27.99M | (m) | (m) | (m) | 1.06× |
| 2025-06-30 | (m) | (m) | $-30.73M | (m) | (m) | (m) | (m) | $-32.99M | (m) | (m) | (m) | 0.93× |
| 2025-03-31 | (m) | (m) | $-31.11M | (m) | (m) | (m) | (m) | $-33.30M | (m) | (m) | (m) | 0.93× |
| 2024-12-31 | $-28.48M | (m) | $-28.47M | $4.00K | (m) | (m) | (m) | $-33.97M | (m) | (m) | (m) | 0.84× |
| 2024-09-30 | $-25.58M | (m) | $-25.55M | $33.00K | (m) | (m) | (m) | $-34.27M | (m) | (m) | (m) | 0.75× |
| 2024-06-30 | $-22.95M | (m) | $-22.86M | $91.00K | (m) | (m) | (m) | $-31.08M | (m) | (m) | (m) | 0.74× |
| 2024-03-31 | (m) | (m) | $-20.56M | (m) | (m) | (m) | (m) | $-28.77M | (m) | (m) | (m) | 0.71× |
| 2023-12-31 | $-16.16M | (m) | $-16.02M | $147.00K | (m) | (m) | (m) | $-25.79M | (m) | (m) | (m) | 0.62× |
| 2023-09-30 | $-20.87M | (m) | $-20.75M | $127.00K | (m) | (m) | (m) | $-22.83M | (m) | (m) | (m) | 0.91× |
| 2023-06-30 | $-16.68M | (m) | $-16.59M | $92.00K | (m) | (m) | (m) | $-22.70M | (m) | (m) | (m) | 0.73× |
| 2023-03-31 | $-18.33M | (m) | $-18.25M | $78.00K | (m) | (m) | (m) | $-23.73M | (m) | (m) | (m) | 0.77× |
| 2022-12-31 | $-18.70M | (m) | $-18.53M | $171.00K | (m) | (m) | (m) | $-21.40M | (m) | (m) | (m) | 0.87× |
| 2022-09-30 | (m) | (m) | $-8.25M | (m) | (m) | (m) | (m) | $-23.55M | (m) | (m) | (m) | 0.35× |
| 2022-06-30 | (m) | (m) | $-10.29M | (m) | (m) | (m) | (m) | $-20.04M | (m) | (m) | (m) | 0.51× |
| 2022-03-31 | (m) | (m) | $-5.85M | (m) | (m) | (m) | (m) | $-15.78M | (m) | (m) | (m) | 0.37× |
| 2021-12-31 | $-3.66M | (m) | $-3.63M | $27.00K | (m) | (m) | (m) | $-11.72M | (m) | (m) | (m) | 0.31× |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $-5.11M | (m) | (m) | (m) | (m) |
| 2020-12-31 | $-3.44M | (m) | $-3.43M | $10.00K | (m) | (m) | (m) | $-7.84M | (m) | (m) | (m) | 0.44× |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |